Key result
RU 42173, a new beta-adrenergic stimulant, dose-dependently inhibited bronchospasm in vitro and in vivo with a rapid onset and prolonged duration of action similar to salbutamol.
Why the study?
Does RU 42173 inhibit bronchospasm in preclinical models compared to salbutamol and isoprenaline?
Does RU 42173 inhibit bronchospasm in preclinical models compared to salbutamol and isoprenaline?
RU 42173 is a novel beta-adrenergic stimulant with potent, rapid, and prolonged bronchodilator effects comparable to salbutamol in preclinical models.
Answers are grounded in this paper and cite their sources.
Should not yet inform clinical use; leaves open translation of RU 42173 from animal models to human bronchospasm.
The bronchodilator properties of RU 42173, a new beta-adrenergic stimulant with an original structure, as a cyclic analogue of an arylethanolamine, have been evaluated on different in vitro and in vivo models and compared with those of salbutamol and isoprenaline. RU 42173 equipotently inhibited histamine-, acetylcholine-, and KCl-induced contractions in isolated guinea pig trachea or small bronchus and in isolated human bronchus. When administered to guinea pigs by the IV or aerosol route, RU 42173 dose-dependently inhibited bronchospasm induced by histamine, acetylcholine, and methacholine. It also inhibited PAF-induced bronchoconstriction and PAF-induced hyperreactivity to histamine. Moreover, RU 42173 had a rapid onset and prolonged duration of action. The potency of RU 42173 was similar to that of salbutamol.
No takes yet. Share an insight, caveat, or question.
Fichelle et al. (1988) studied Bronchospasm. RU 42173 vs. Salbutamol and isoprenaline was evaluated on Inhibition of bronchospasm and contractions. RU 42173, a new beta-adrenergic stimulant, dose-dependently inhibited bronchospasm in vitro and in vivo with a rapid onset and prolonged duration of action similar to salbutamol.
Synapse has enriched 10 related papers. Consider them for comparative context: